Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation?

Prostaglandins and Other Lipid Mediators

Volumn 98, Issue 3-4, 2012, Pages 75-85

  Fava, Cristiano ^a,b   Ricci, Marco ^a   Melander, Olle ^b   Minuz, Pietro ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b LUND UNIVERSITY   (Sweden)

Author keywords

20 Hydroxyeicosatetraenoic acid; Cytochrome P450; Epoxyeicosatrienoic acids; Genetic polymorphism; Hypertension; Sex

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; CYTOCHROME P450 4A11; CYTOCHROME P450 4F2; EPOXYICOSATRIENOIC ACID; ICOSANOID; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; POLYMORPHISM, GENETIC; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84864488076     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2011.11.007     Document Type: Review

References (108)

1. J.A. Cutler, P.D. Sorlie, M. Wolz, T. Thom, L.E. Fields, and E.J. Roccella Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004 Hypertension 52 5 2008 818 827
2. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 9349 2002 1903 1913
3. M. Ezzati, S. Oza, G. Danaei, and C.J. Murray Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States Circulation 117 7 2008 905 914
4. C. Fava, P. Burri, P. Almgren, L. Groop, U.L. Hulthen, and O. Melander Heritability of ambulatory and office blood pressure phenotypes in Swedish families J Hypertens 22 9 2004 1717 1721
5. R.P. Lifton, A.G. Gharavi, and D.S. Geller Molecular mechanisms of human hypertension Cell 104 4 2001 545 556
6. W. Ji, J.N. Foo, and B.J. O'Roak Rare independent mutations in renal salt handling genes contribute to blood pressure variation Nat Genet 40 5 2008 592 599
7. C. Fava, M. Montagnana, and L. Rosberg Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure Hum Mol Genet 17 3 2008 413 418
8. D. Levy, G.B. Ehret, and K. Rice Genome-wide association study of blood pressure and hypertension Nat Genet 41 6 2009 677 687
9. C. Newton-Cheh, T. Johnson, and V. Gateva Genome-wide association study identifies eight loci associated with blood pressure Nat Genet 41 6 2009 666 676
10. S. Padmanabhan, O. Melander, and T. Johnson Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension PLoS Genet 6 10 2010 e1001177
11. Y.F. Chen Sexual dimorphism of hypertension Curr Opin Nephrol Hypertens 5 1996 181 185
12. A. Pechere-Bertschi, and M. Burnier Gonadal steroids, salt-sensitivity and renal function Curr Opin Nephrol Hypertens 16 1 2007 16 21
13. J.F. Reckelhoff Gender differences in the regulation of blood pressure Hypertension 37 5 2001 1199 1208
14. L.L. Yanes, and J.F. Reckelhoff Postmenopausal hypertension Am J Hypertens 24 7 2011 740 749
15. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 6 2003 523 534
16. H. Sumino, S. Ichikawa, and H. Kumakura Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women Hypertens Res 26 5 2003 369 376
17. J. Ichikawa, H. Sumino, S. Ichikawa, and M. Ozaki Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women Am J Hypertens 19 7 2006 744 749
18. G.B. Ehret, P.B. Munroe, and K.M. Rice Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk Nature 478 7367 2011 103 109
19. J.H. Capdevila, and J.R. Falck Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases Prostaglandins Other Lipid Mediat 68-69 2002 325 344
20. R.J. Roman P-450 metabolites of arachidonic acid in the control of cardiovascular function Physiol Rev 82 1 2002 131 185
21. C.C. Wu, and M.L. Schwartzman The role of 20-HETE in androgen-mediated hypertension Prostaglandins Other Lipid Mediat 2011 10.1016/j.prostaglandins. 2011.06.006
22. J.D. Imig Targeting epoxides for organ damage in hypertension J Cardiovasc Pharmacol 56 4 2010 329 335
23. B.T. Larsen, W.B. Campbell, and D.D. Gutterman Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system Trends Pharmacol Sci 28 1 2007 32 38
24. M.A. Carroll, M. Balazy, P. Margiotta, D.D. Huang, J.R. Falck, and J.C. McGiff Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides Am J Physiol 271 4 Pt 2 1996 R863 R869
25. A. Sarkis, B. Lopez, and R.J. Roman Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension Curr Opin Nephrol Hypertens 13 2 2004 205 214
26. V.R. Holla, F. Adas, and J.D. Imig Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension Proc Natl Acad Sci U S A 98 9 2001 5211 5216
27. K. Nakagawa, J.S. Marji, M.L. Schwartzman, M.R. Waterman, and J.H. Capdevila Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension Am J Physiol Regul Integr Comp Physiol 284 4 2003 R1055 R1062
28. C.J. Sinal, M. Miyata, M. Tohkin, K. Nagata, J.R. Bend, and F.J. Gonzalez Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation J Biol Chem 275 51 2000 40504 40510
29. H. Singh, and M.L. Schwartzman Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension Pharmacol Rep 60 1 2008 29 37
30. H. Singh, J. Cheng, and H. Deng Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension Hypertension 50 1 2007 123 129
31. Y. Zhou, S. Lin, and H.H. Chang Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet Am J Hypertens 18 4 Pt 1 2005 530 537
32. P. Fidelis, L. Wilson, K. Thomas, M. Villalobos, and A.O. Oyekan Renal function and vasomotor activity in mice lacking the Cyp4a14 gene Exp Biol Med (Maywood) 235 11 2010 1365 1374
33. D.N. Muller, C. Schmidt, and E. Barbosa-Sicard Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation Biochem J 403 1 2007 109 118
34. L.L. Yanes, R. Lima, and M. Moulana Postmenopausal hypertension: role of 20-HETE Am J Physiol Regul Integr Comp Physiol 300 6 2011 R1543 R1548
35. M.H. Wang, A. Smith, and Y. Zhou Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension Hypertension 42 4 2003 594 599
36. Y. Zhou, H. Huang, and H.H. Chang Induction of renal 20- hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats J Pharmacol Exp Ther 317 1 2006 11 18
37. H. Huang, C. Morisseau, and J. Wang Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats Am J Physiol Renal Physiol 293 1 2007 F342 F349
38. J.D. Imig Epoxygenase metabolites. Epithelial and vascular actions Mol Biotechnol 16 3 2000 233 251
39. R.H. Elbekai, and A.O.S. El-Kadi Cytochrome P450 enzymes: central players in cardiovascular health and disease Pharmacol Ther 112 2 2006 564 587
40. P.K. Powell, I. Wolf, R. Jin, and J.M. Lasker Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11 J Pharmacol Exp Ther 285 3 1998 1327 1336
41. A.E. Enayetallah, R.A. French, M.S. Thibodeau, and D.F. Grant Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues J Histochem Cytochem 52 4 2004 447 454
42. Z. Yu, B.B. Davis, and C. Morisseau Vascular localization of soluble epoxide hydrolase in the human kidney Am J Physiol Renal Physiol 286 2004 F720 F726
43. P. Sura, R. Sura, A.E. Enayetallah, and Grant D.F. Distribution Expression of soluble epoxide hydrolase in human brain J Histochem Cytochem 56 6 2008 551 559
44. C.L. Laffer, M. Laniado-Schwartzman, M.H. Wang, A. Nasjletti, and F. Elijovich Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension Circulation 107 4 2003 574 578
45. C.L. Laffer, M. Laniado-Schwartzman, M.H. Wang, A. Nasjletti, and F. Elijovich 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension Hypertension 41 3 pt 2 2003 703 708
46. C.L. Laffer, M. Laniado-Schwartzman, A. Nasjletti, and F. Elijovich 20-HETE and circulating insulin in essential hypertension with obesity Hypertension 43 2 2004 388 392
47. N.C. Ward, J.M. Hodgson, I.B. Puddey, L.J. Beilin, and K.D. Croft 20-Hydroxyeicosatetraenoic acid is not associated with circulating insulin in lean to overweight humans Diabetes Res Clin Pract 74 2 2006
48. N.C. Ward, I.B. Puddey, J.M. Hodgson, L.J. Beilin, and K.D. Croft Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects Free Radic Biol Med 38 8 2005 1032 1036
49. N.C. Ward, J. Rivera, and J. Hodgson Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans Circulation 110 4 2004 438 443
50. S. Taddei, D. Versari, and A. Cipriano Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients J Am Coll Cardiol 48 3 2006 508 515
51. P. Minuz, H. Jiang, and C. Fava Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease Hypertension 51 5 2008 1379 1385
52. B.N. Zordoky, and A.O. El-Kadi Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases Pharmacol Ther 125 3 2010 446 463
53. Y. Xu, H. Ding, and J. Peng Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease Pharmacogenet Genomics 21 8 2011 489 494
54. D. Dai, D.C. Zeldin, and J.A. Blaisdell Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 7 2001 597 607
55. M.S. Lundblad, K. Stark, E. Eliasson, E. Oliw, and A. Rane Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes Biochem Biophys Res Commun 327 4 2005 1052 1057
56. L.M. King, J.V. Gainer, and G.L. David Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension Pharmacogenet Genomics 15 1 2005 7 13
57. A.W. Dreisbach, S. Japa, and A. Sigel The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension Am J Hypertens 18 10 2005 1276 1281
58. U. Yasar, A.M. Bennet, and E. Eliasson Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction Pharmacogenetics 13 12 2003 715 720
59. E. Haschke-Becher, J. Kirchheiner, and O. Trummer Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort Pharmacogenomics 11 10 2010 1359 1365
60. L.E. Visser, R.H. van Schaik, and A.H. Jan Danser The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9 Pharmacogenet Genomics 17 7 2007 473 479
61. D. Kaur-Knudsen, S.E. Bojesen, and B.G. Nordestgaard Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals Pharmacogenomics J 9 5 2009 327 332
62. B. Ercan, L. Ayaz, D. Cicek, and L. Tamer Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis Cell Biochem Funct 26 3 2008 309 313
63. K.D. Marciante, R.A. Totah, and S.R. Heckbert Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke Pharmacogenet Genomics 18 6 2008 535 543
64. L.M. King, J.X. Ma, and S. Srettabunjong Cloning of CYP2J2 gene and identification of functional polymorphisms Mol Pharmacol 61 4 2002 840 852
65. M. Spiecker, H. Darius, and T. Hankeln Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 Circulation 110 15 2004 2132 2136
66. M. Spiecker, D.C. Zeldin, A. Mugge, G. Tenderich, R. Korfer, and J.K. Liao Reduced human myocardial mRNA expression of CYP2J2 in individuals with the G-50T promoter polymorphism Circulation 114 18 2006 [Abstract]
67. P.Y. Liu, Y.H. Li, and T.H. Chao Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction Atherosclerosis 195 1 2007 199 206
68. S.N. Wu, Y. Zhang, and C.O. Gardner Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension Ann Hum Genet 71 pt 4 2007 519 525
69. C. Fava, M. Montagnana, and P. Almgren The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes J Hypertens 28 2 2010 294 299
70. J. Borgel, D. Bulut, and C. Hanefeld The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile BMC Cardiovasc Disord 8 2008 41
71. M.M. Hoffmann, P. Bugert, and U. Seelhorst The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study Clin Chem 53 3 2007 539 540
72. C.R. Lee, K.E. North, M.S. Bray, D.J. Couper, G. Heiss, and D.C. Zeldin CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study Pharmacogenet Genomics 17 5 2007 349 358
73. L. Zhang, H. Ding, and J. Yan Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population Pharmacogenet Genomics 18 1 2008 45 51
74. J.V. Gainer, A. Bellamine, and E.P. Dawson Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension Circulation 111 1 2005 63 69
75. N.C. Ward, I.J. Tsai, and A. Barden A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure Hypertension 51 5 2008 1393 1398
76. C.L. Laffer, J.V. Gainer, and M.R. Waterman The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension Hypertension 51 3 2008 767 772
77. J.M. Lasker, W.B. Chen, I. Wolf, B.P. Bloswick, P.D. Wilson, and P.K. Powell Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11 J Biol Chem 275 6 2000 4118 4126
78. M. Hermann, J.P. Hellermann, and K. Quitzau CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease - the ENCORE Trials Atherosclerosis 207 2 2009 476 479
79. B. Mayer, W. Lieb, and A. Gotz Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy Hypertension 46 4 2005 766 771
80. C. Fava, M. Montagnana, and P. Almgren The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure Hypertension 52 2 2008 373 380
81. B. Mayer, W. Lieb, and A. Gotz Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction J Hypertens 24 10 2006 1965 1970
82. Z. Fu, T. Nakayama, and N. Sato A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men J Hypertens 26 3 2008 453 461
83. Z. Fu, T. Nakayama, and N. Sato Haplotype-based case study of human CYP4A11 gene and cerebral infarction in Japanese subject Endocrine 33 2 2008 215 222
84. H. Ding, G. Cui, and L. Zhang Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population Pharmacogenet Genomics 20 3 2010 187 194
85. J.V. Gainer, M.S. Lipkowitz, and C. Yu Association of a CYP4A11 variant and blood pressure in black men J Am Soc Nephrol 19 8 2008 1606 1612
86. D.E. Stec, R.J. Roman, A. Flasch, and M.J. Rieder Functional polymorphism in human CYP4F2 decreases 20-HETE production Physiol Genomics 2007 30
87. M.G. McDonald, M.J. Rieder, M. Nakano, C.K. Hsia, and A.E. Rettie CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant Mol Pharmacol 75 6 2009 1337 1346
88. S.A. Bardowell, D.E. Stec, and R.S. Parker Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}-hydroxylase specific activity J Nutr 140 11 2010 1901 1906
89. A. Munshi, V. Sharma, S. Kaul, A. Al-Hazzani, A.A. Alshatwi, and G. Shafi Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke Mol Biol Rep 2011 [Epub ahead of print]
90. Z. Fu, T. Nakayama, and N. Sato Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects Hypertens Res 31 9 2008 1719 1726
91. H. Liu, Y. Zhao, and D. Nie Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension J Am Soc Nephrol 19 4 2008 714 721
92. Z. Fu, T. Nakayama, and N. Sato A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men Am J Hypertens 21 11 2008 1216 1223
93. Z. Fu, T. Nakayama, and N. Sato A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men Mol Genet Metab 96 3 2009 145 147
94. B.D. Przybyla-Zawislak, P.K. Srivastava, and J. Vazquez-Matias Polymorphisms in human soluble epoxide hydrolase Mol Pharmacol 64 2 2003 482 490
95. M. Sandberg, C. Hassett, E.T. Adman, J. Meijer, and C.J. Omiecinski Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms J Biol Chem 275 37 2000 28873 28881
96. P.K. Srivastava, V.K. Sharma, D.S. Kalonia, and D.F. Grant Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure Arch Biochem Biophys 427 2 2004 164 169
97. C.R. Lee, K.E. North, and M.S. Bray Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study Hum Mol Genet 15 10 2006 1640 1649
98. I.P. Koerner, R. Jacks, and A.E. DeBarber Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury J Neurosci 27 17 2007 4642 4649
99. C.R. Lee, M. Pretorius, and R.N. Schuck Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans Hypertension 57 1 2011 116 122
100. C. Fava, M. Montagnana, and E. Danese Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes Pharmacogenet Genomics 20 2 2010 94 103
101. M. Fornage, C.R. Lee, and P.A. Doris The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke Hum Mol Genet 14 19 2005 2829 2837
102. A. Gschwendtner, S. Ripke, and T. Freilinger Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans Stroke 39 5 2008 1593 1596
103. Q. Wei, P.A. Doris, and M.V. Pollizotto Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking Atherosclerosis 190 1 2007 26 34
104. P. August Hypertension in men J Clin Endocrinol Metab 84 1999 3451 3454
105. C. Bertrand-Thiebault, L. Ferrari, and O. Boutherin-Falson Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis Clin Exp Pharmacol Physiol 31 5-6 2004 295 301
106. C. Arnold, M. Markovic, and K. Blossey Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids J Biol Chem 285 43 2010 32720 32733
107. A.V. Polonikov, V.P. Ivanov, and M.A. Solodilova A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population Dis Markers 24 2 2008 119 126
108. S. Deng, G. Zhu, and F. Liu CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population Prog Neuropsychopharmacol Biol Psychiatry 34 4 2010 664 668